title: Overexpression of ANLN contributed to poor prognosis of anthracycline-based chemotherapy in breast cancer patients.
abstract: To investigate the associations of ANLN expression with prognosis of breast cancer and clinical outcome of anthracycline-based chemotherapy.
  
  
  
  This study enrolled 308 breast cancer patients in which 264 of them received anthracycline-based chemotherapy. Immunohistochemistry was used to detect ANLN expression level of the patients. Clinical characteristics of the patients were collected, and associations of ANLN expression with prognosis were analyzed.
  
  
  
  Our results showed that ANLN expression was associated with survival of breast cancer patients, and it was also related to clinical outcome of patients received anthracycline-based chemotherapy. Breast cancer patients with high expression of ANLN would have poor prognosis and poor clinical outcome to anthracycline-based chemotherapy.
  
  
  
  ANLN could be an independent prognosis predictor for breast cancer, and its expression might be used to predict the anthracycline-based chemotherapy clinical outcome in breast cancer patients.
authors.affiliation: Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
authors.forename: Zhan
authors.initials: Z
authors.lastname: Wang
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.|Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410078, People's Republic of China.
authors.forename: Juan
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
authors.forename: Mei-Zuo
authors.initials: MZ
authors.lastname: Zhong
authors.affiliation: Hunan Province Clinic Meditech Research Center for Breast Cancer, Changsha, 410008, People's Republic of China.
authors.forename: Juan
authors.initials: J
authors.lastname: Huang
authors.affiliation: Hunan Province Clinic Meditech Research Center for Breast Cancer, Changsha, 410008, People's Republic of China.
authors.forename: Yuan-Ping
authors.initials: YP
authors.lastname: Hu
authors.affiliation: Department of Pathology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.
authors.forename: De-Yun
authors.initials: DY
authors.lastname: Feng
authors.affiliation: Department of Pathology, The third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
authors.forename: Zhi-Jiao
authors.initials: ZJ
authors.lastname: Zhou
authors.affiliation: Department of Pain, The third Xiangya Hospital, Central South University, Changsha, 410013, People's Republic of China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Luo
authors.affiliation: Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China.|Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, 410078, People's Republic of China.
authors.forename: Zhao-Qian
authors.initials: ZQ
authors.lastname: Liu
authors.affiliation: Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. jwz903@126.com.
authors.forename: Wu-Zhong
authors.initials: WZ
authors.lastname: Jiang
authors.affiliation: Department of Oncology, Xiangya Hospital, Central South University, Changsha, 410008, People's Republic of China. zhouweibing298@163.com.
authors.forename: Wei-Bing
authors.initials: WB
authors.lastname: Zhou
mesh_terms: D000368:Aged; D018943:Anthracyclines / Q000627:therapeutic use*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008840:Microfilament Proteins / Q000096:biosynthesis* / Q000235:genetics; D008875:Middle Aged; D011379:Prognosis
chemical_list: C000591059:ANLN protein, human; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; D008840:Microfilament Proteins
keywords: ANLN; Anthracycline; Breast cancer; Prognosis